+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID07173166

Study of Physical Activity and Nutrition to Reduce Neurotoxicity in Adults with Hematologic Cancer Receiving CAR-T Therapy

Led by Instituto de Investigacion Sanitaria INCLIVA · Updated on 2026-07-28

338

Participants Needed

2

Research Sites

61 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating two non-drug approaches to reduce neurotoxicity caused by CAR-T cell therapy in adults aged 18 to 80 years with hematologic cancer. The study aims to determine whether a structured physical activity program alone or combined with nutritional recommendations can better lower the risk or severity of neurotoxicity compared to no intervention. This trial is a randomized, multicenter controlled study conducted between July 2025 and July 2027. Participants will be randomly assigned to one of three groups a physical activity program, a combined physical activity and Mediterranean diet-based nutritional program, or a control group receiving no intervention. The exercise program includes aerobic and resistance sessions supervised by physiotherapists, adapted to the participants fitness level. Nutritional guidance emphasizes anti-inflammatory and antioxidant-rich foods. Interventions start one month before CAR-T therapy and continue at least one month after treatment. Participants will be monitored weekly before, during, and for four weeks after CAR-T therapy by a multidisciplinary team. Assessments include neurotoxicity severity, physical activity levels, nutritional status, functional independence, quality of life, and adherence to interventions. Evaluations occur at baseline, during treatment, and post-treatment for up to 15 days after CAR-T therapy. Comprehensive symptom and health data will be collected throughout the study, which is sponsored by Instituto de Investigacion Sanitaria INCLIVA.

CONDITIONS

Brief Title

Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy

Research Team

M

Marina Hernandez Aliaga, RN, MSc, PhD(c)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here